Articles and Videos
The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids....
InMed and BayMedica Host First Webinar Together Following News of Signing Definitive Agreement on Acquisition
InMed and BayMedica hosted a live webinar to talk about InMed's acquisition of BayMedica, how it positions the company as a leader in the manufacturing...
BayMedica Acquisition Propels InMed (NASDAQ: INM) Into Leadership Role In Manufacturing & Commercialization of Rare Cannabinoids
Beyond the well-known cannabinoids of THC and CBD, there’s a whole world of rare cannabinoids. Indeed, there are more than 100 rare cannabinoids that have been...
Journalist Vivienne Parry Interviews InMed CEO, Eric A. Adams and BayMedica Co-founder, Shane Johnson, to Talk About their Shared Vision for the Combined Company
On September 13th, journalist Vivienne Parry interviewed InMed Pharmaceuticals' President and CEO, Eric A. Adams, and BayMedica's co-founder, Shane Johnson. In their first interview together,...
Source: Edison TV
InMed Pharmaceuticals Inc. Enters Agreement For ‘Transformative’ Acquisition Of Leading Manufacturer Of Rare Cannabinoids
InMed Pharmaceuticals, a leader in the manufacturing and clinical development of rare cannabinoids, has signed a definitive agreement to acquire BayMedica Inc., a private, U.S.-based...
What impacts the cost of manufacturing synthesized cannabinoids?
What affects the cost of cannabinoid manufacturing? To make rare cannabinoids commercially viable products, a high yielding and cost-effective method is required. What impacts the...
